Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.
Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T.
Alping P, et al. Among authors: fink k.
Ann Neurol. 2020 May;87(5):688-699. doi: 10.1002/ana.25701. Epub 2020 Mar 9.
Ann Neurol. 2020.
PMID: 32056253
Free article.